Clinical utility of plasma Epstein-Barr virus DNA andERCC1single nucleotide polymorphism in nasopharyngeal carcinoma

ERCC1 Cys8092Ala and XRCC1 Arg399Gln Polymorphisms Predict Progression-Free Survival after Curative Radiotherapy for Nasopharyngeal Carcinoma

(2014) Hekun Jin et al.   PLoS One

Polymorphisms in ERCC1 C8092A predict progression-free survival in metastatic/recurrent nasopharyngeal carcinoma treated with cisplatin-based chemotherapy

(2013) Cui Chen et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

An International Collaboration to Harmonize the Quantitative Plasma Epstein-Barr Virus DNA Assay for Future Biomarker-Guided Trials in Nasopharyngeal Carcinoma

(2013) Q.-T. Le et al.   CLINICAL CANCER RESEARCH

Association of ERCC1-C118T and -C8092A polymorphisms with lung cancer risk and survival of advanced-stage non-small cell lung cancer patients receiving platinum-based chemotherapy: A pooled analysis based on 39 reports

(2013) Tong-Peng Xu et al.   GENE

Excision Repair Cross-Complementation group 1 (ERCC1) C118T SNP does not affect cellular response to oxaliplatin

(2013) Lieke H. van Huis-Tanja et al.   MUTATION RESEARCH-FUNDAMENTAL AND MOLECULAR MECHANISMS OF MUTAGENESIS

ERCC1 Isoform Expression and DNA Repair in Non–Small-Cell Lung Cancer

(2013) Luc Friboulet et al.   NEW ENGLAND JOURNAL OF MEDICINE

The association between the ERCC1/2 polymorphisms and the clinical outcomes of the platinum-based chemotherapy in non-small cell lung cancer (NSCLC): a systematic review and meta-analysis

(2013) Yanlong Yang et al.   TUMOR BIOLOGY

Cisplatin benefit is predicted by immunohistochemical analysis of DNA repair proteins in squamous cell carcinoma but not adenocarcinoma: theranostic modeling by NSCLC constituent histological subclasses

(2012) W. E. Pierceall et al.   ANNALS OF ONCOLOGY

Nasopharyngeal cancer: EHNS-ESMO-ESTRO Clinical Practice Guidelines for diagnosis, treatment and follow-up

(2012) A. T. C. Chan et al.   ANNALS OF ONCOLOGY

Reporting recommendations for tumor marker prognostic studies (REMARK): explanation and elaboration

(2012) Douglas G Altman et al.   BMC Medicine

Assessment of ERCC1 and XPF Protein Expression Using Quantitative Immunohistochemistry in Nasopharyngeal Carcinoma Patients Undergoing Curative Intent Treatment

(2012) Amanda Jagdis et al.   INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS

Expression of ERCC1 predicts clinical outcome in locoregionally advanced nasopharyngeal carcinoma treated with cisplatin-based induction chemotherapy

(2012) Pei-Yu Huang et al.   ORAL ONCOLOGY

Expression of Excision Repair Cross-Complementation Group 1 as Predictive Marker for Nasopharyngeal Cancer Treated With Concurrent Chemoradiotherapy

(2011) Jong-Mu Sun et al.   INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS

Association between polymorphisms of DNA repair genes and survival of advanced NSCLC patients treated with platinum-based chemotherapy

(2011) Shengxiang Ren et al.   LUNG CANCER

The ERCC1 N118N polymorphism does not change cellular ERCC1 protein expression or platinum sensitivity

(2011) Rui Gao et al.   MUTATION RESEARCH-FUNDAMENTAL AND MOLECULAR MECHANISMS OF MUTAGENESIS

ERCC1 and histopathology in advanced NSCLC patients randomized in a large multicenter phase III trial

(2010) A. C. Vilmar et al.   ANNALS OF ONCOLOGY

Can the Analysis of ERCC1 Expression Contribute to Individualized Therapy in Nasopharyngeal Carcinoma?

(2010) Siu Hong Chan et al.   INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS

No evidence of an association of ERCC1 and ERCC2 polymorphisms with clinical outcomes of platinum-based chemotherapies in non-small cell lung cancer: A meta-analysis

(2010) Ming Yin et al.   LUNG CANCER

High expression of excision repair cross-complementation group1 protein predicts poor outcome in patients with nasopharyngeal cancer

(2010) Hyun Woo Lee et al.   ORAL ONCOLOGY

Multicenter phase II study of gemcitabine and oxaliplatin in advanced nasopharyngeal carcinoma--correlation with excision repair cross-complementing-1 polymorphisms

(2009) B. B. Y. Ma et al.   ANNALS OF ONCOLOGY

Effects of excision repair cross-complementation group 1 (ERCC1) single nucleotide polymorphisms on the prognosis of non-small cell lung cancer patients

(2009) Tomoyoshi Takenaka et al.   LUNG CANCER

ERCC1codon 118 C→T polymorphism associated withERCC1expression and outcome of FOLFOX-4 treatment in Asian patients with metastatic colorectal carcinoma

(2008) Peter Mu-Hsin Chang et al.   CANCER SCIENCE

A distinct ERCC1 haplotype is associated with mRNA expression levels in prostate cancer patients

(2008) A. Woelfelschneider et al.   CARCINOGENESIS

Relationship BetweenERCC1Polymorphisms, Disease Progression, and Survival in the Gynecologic Oncology Group Phase III Trial of Intraperitoneal Versus Intravenous Cisplatin and Paclitaxel for Stage III Epithelial Ovarian Cancer

(2008) Thomas C. Krivak et al.   JOURNAL OF CLINICAL ONCOLOGY

Excision repair cross-complementation group 1 (ERCC1) in platinum-based treatment of non-small cell lung cancer with special emphasis on carboplatin: A review of current literature

(2008) Adam Vilmar et al.   LUNG CANCER

Association of ERCC1 polymorphisms and susceptibility to nasopharyngeal carcinoma

(2008) Zhi-Hui Yang et al.   MOLECULAR CARCINOGENESIS

ERCC1 polymorphism, expression and clinical outcome of oxaliplatin-based adjuvant chemotherapy in gastric cancer

(2008) Zhao-Hui Huang et al.   WORLD JOURNAL OF GASTROENTEROLOGY